Nilsson et al. 9 found that the EML4–ALK fusion transcripts in the platelets are much lower in the patients with NSCLC with the effective anti‐EML4–ALK crizotinib therapy compared with the patients without response for the anti‐EML4–ALK crizotinib therapy. The gene discussed is ALK; the disease is non-small cell lung carcinoma.